Literature DB >> 22064529

Low prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates among Connecticut veterans.

Susan L Fink1, Richard A Martinello, Sheldon M Campbell, Thomas S Murray.   

Abstract

The Etest glycopeptide resistance detection identified two potential heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) isolates from a screen of 288 methicillin-resistant Staphylococcus aureus (MRSA) isolates from patients at a Connecticut Veterans Hospital. However, the two isolates did not meet the criteria for hVISA by the population analysis profile-area under the curve analysis, arguing against routine screening for hVISA in this low prevalence population.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22064529      PMCID： PMC3256079          DOI： 10.1128/AAC.05024-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.

Authors:  Catherine Liu; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 2.  Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective.

Authors:  B P Howden; P B Ward; P D R Johnson; P G P Charles; M L Grayson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

3.  Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area.

Authors:  Jose M Eguia; Catherine Liu; Matthew Moore; Elizabeth M Wrone; Joan Pont; Julie L Gerberding; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2005-04-19       Impact factor: 9.079

4.  Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin.

Authors:  J Ariza; M Pujol; J Cabo; C Peña; N Fernández; J Liñares; J Ayats; F Gudiol
Journal:  Lancet       Date:  1999-05-08       Impact factor: 79.321

5.  Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period.

Authors:  Guiqing Wang; Janet F Hindler; Kevin W Ward; David A Bruckner
Journal:  J Clin Microbiol       Date:  2006-09-06       Impact factor: 5.948

6.  Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.

Authors:  Patrick G P Charles; Peter B Ward; Paul D R Johnson; Benjamin P Howden; M Lindsay Grayson
Journal:  Clin Infect Dis       Date:  2004-01-12       Impact factor: 9.079

7.  Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA.

Authors:  Anne Yusof; Anette Engelhardt; Asa Karlsson; Lina Bylund; Pamela Vidh; Karen Mills; Mandy Wootton; Timothy R Walsh
Journal:  J Clin Microbiol       Date:  2008-07-02       Impact factor: 5.948

8.  Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides.

Authors:  Steven N Leonard; Kerri L Rossi; Karly L Newton; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2009-01-09       Impact factor: 5.790

9.  Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia.

Authors:  Yasmin Maor; Michal Hagin; Natasha Belausov; Nathan Keller; Debbi Ben-David; Galia Rahav
Journal:  J Infect Dis       Date:  2009-03-01       Impact factor: 5.226

10.  A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA).

Authors:  Andreas Voss; Johan W Mouton; Erika P van Elzakker; Ron G Hendrix; Wil Goessens; Jan A Kluytmans; Paul F Krabbe; Han J de Neeling; Jacobus H Sloos; Nefise Oztoprak; Robin A Howe; Timothy R Walsh
Journal:  Ann Clin Microbiol Antimicrob       Date:  2007-09-24       Impact factor: 3.944
View more
  2 in total

Review 1.  Antimicrobial heteroresistance: an emerging field in need of clarity.

Authors:  Omar M El-Halfawy; Miguel A Valvano
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

Review 2.  Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates.

Authors:  Shanshan Zhang; Xiaoxi Sun; Wenjiao Chang; Yuanyuan Dai; Xiaoling Ma
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.